MedPath

Effect of pemafibrate on lipid and bile acid metabolism in patients with fatty liver or primary biliary cholangitis

Not Applicable
Recruiting
Conditions
fatty liver, PBC
Registration Number
JPRN-UMIN000039125
Lead Sponsor
Tokai University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1. severe liver dysfunction (C-P B or C) 2. moderate or severe renal dysfunction 3. gallstone 4. pregnant women

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hepatic fat evaluated by MRS in 6 months (fatty liver patients) Serum ALP levels in 6 months (PBC patients)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath